OpenAI is going to use and profit from the AI-aided drug

On 4 February, it was reported that Chief Executive Officer Sam Ottman of OpenAI had indicated that the company might consider investing in companies or providing subsidies for the development of new drugs or treatments using its artificial intelligence technology in large quantities and that it might receive returns through the collection of patents or royalties. According to Otman, artificial intelligence developers can choose to work with pharmaceutical companies to share the cost of using their artificial intelligence models and subsequently obtain a “specific share” from the company's research. He noted that they had not yet had such cooperation. (FIA)